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Nausea and vomiting induced by chemotherapy is a variable
response related to the nature and intensity of treatment and
patient susceptility. The mechanism whereby chemotherapy
evokes nausea and vomiting is uncertain but recently, the
ability of 5-HT3 receptor antagonists to antagonise chemo-
therapy induced emesis in animals (Costall et al., 1986; Miner
& Sanger, 1986) and man (Cunningham et al., 1987; Lei-
bundgut & Lancranjan, 1987; Kris et al., 1989) has focused
interest on the role of 5-hydroxytryptamine (5-HT). It has
been hypothesised that emetogenic chemotherapeutic agents
may release 5-HT to trigger the emetic reflex via 5-HT3
receptors located at central sites or on the afferent vagus
nerve (Andrews et al., 1988; Hawthorne et al., 1988; Higgins
et al., 1989). 5-HT is found in high concentration in the
enterochromaffin cells and platelets and a release of 5-HT
from such sites would be expected to elevate the circulating
levels of 5-HT (Verbeuren, 1989). The present studies were
designed to investigate whether plasma 5-HT levels are in-
creased during chemotherapy in patients receiving the potent
emetogen cisplatin.
Ten male patients aged between 20 and 39 years (median
30 years) undergoing cisplatinum-containing cytotoxic ther-
apy for metastatic germ cell tumour of the testis (teratoma
eight patients, seminoma two patients) were studied during
the first 24 h of a 5-day course of treatment. Commonly used
schedules of treatment were employed, mainly the BEP
regime (bleomycin, etoposide and cisplatinum). All patients
received pre-chemotherapy antiemetics. Although there were
minor variations in the antiemetic regime to suit individual
patients, the commonly used schedule was lorazepam 2 mg,
metoclopramide 1Omg and dexamethasone 8 mg, all given
intravenously at hour 0, together with further doses of
appropriate drugs on demand in the case of nausea or vomit-
ing developing after the initiation of therapy.
Indwelling cannulae (standard 22 gauge needle or a 22
gauge Venflon) were inserted into a surface vein on the
dorsum of the hand and sealed with attachable rubber caps.
Intravenous cisplatin (20 mg m-2) was administered in 1 litre
of normal saline over 4 h via a surface vein of the opposite
forearm using an IMED 960 volumentric infusion pump.
Blood samples were taken immediately before the infusion of
cisplatin and then at 2, 4, 6, 8, 16 and 24 h after the start of
treatment. Each sampling involved the removal of 5 ml of
blood prior to the collection of a 2.7 ml sample into a 2.7 ml
monovette vial (Startedt). The contents of the vial were
immediately mixed. Within 5-15 min of collection 1 ml
aliquots of the samples were removed and centrifuged at
15,000 g for 3 min to separate the blood cells from the
plasma. Aliquots of 200jil of plasma were then removed,
immediately frozen and stored in liquid nitrogen before
analysis. For the extraction of 5-HT, 8 of 20 mg ml-'
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ascorbic acid (AnalaR Grade BDH), 500 pg il-' N-methyl-5-
HT (internal standard, Sigma) and 600 lI of butanol (Analy-
tical Reagent Grade, May & Baker) was added to each 200ytl
plasma sample and mixed for 10 min before centrifugation at
15,000g for 1 min. The butanol phase was then removed and
added to 900iLl of heptane (Analytical Reagent Grade, May
& Baker) and 100IlI of0.1 mol dm 3 hydrochloric acid (Ana-
lytical Reagent Grade, May & Baker). This was then mixed
for Omin before centrifugation at 15,000g for 1 min. The
5-HT content in 50y1 of the aqueous phase was then assayed
by HPLC with electrochemical detection. The HPLC systems
consisted of a Spectra-Physics IsoChrom liquid chromato-
graphy pump, Wisp 710B automatic injection (Waters) and
hypersil-ODS (250 x 4.6 mm, 5jlm particle size, HPLC Tech-
nology) analytical columns. The electrochemical detector was
a ESA Coulochem (5100A) with 5011 analytical cell (detector
1, + 0.05 V; detector 2, + 0.40 V). Peaks due to oxidation,
at detector 2, in the column elevates were recorded on a
Hewlett-Packard 3392A printing integrator. The HPLC-ECD
system, except the integrator was maintained at 4°C. The
mobile phase for the separation of indoleamines consisted of
a mixture of 0.2 mol dm-3 disodium hydrogen ortho-phos-
phate (AnalaR Grade, BDA) and 0.1 mol dm 3 Citric acid
(AnalaR Grade BDH), pH 6.3, with 11% vol/vol methanol
(Analytical Reagent Grade, May & Baker) and 2.0 mol dm-3
tetraethylammonium bromide (Pariss Grade, Fluka) pumped
at a rate of 1.3 ml min -l.
Vomiting was assessed as an all or none event by the night
sister and respective nurses on the ward. A record was also
made of the time of each emetic episode and if additional
antiemetic treatment was given.
Plasma levels of 5-HT are normally of the order of 0.1-
5 ng ml-' and their detection necessitates a highly sensitive
HPLC-ECD technique; the limits of sensitivity (SNR= 3) of
the present technique was approximately 100 pgml'. Since
the plasma levels of 5-HT are very low compared to the
concentration of 5-HT in the platelets, care was taken in the
sampling procedure to avoid plasma 5-HT contamination by
disruption of platelets. This was achieved by discarding the
first 5ml of withdrawn blood and using the subsequent
2.7 ml sample.
The 5-HT concentration in the plasma before cisplatin
treatment was 386 ± 104 pgml' for the ten patients (mean
± s.e.m.). Measurements taken at 2 h after cisplatin infusion
revealed no changes in the plasma levels of 5-HT but subse-
quently there were marked inter-patient differences. Thus 4 h
readings in patients I and II indicated dramatic 700-800%
increases in plasma 5-HT levels which had returned to con-
trol levels after 6-8 h. In a further two patients III and IV
the control levels were maintained for 6 h before 500-
1,000% increases in plasma 5-HT levels were recorded at 8 h;
measurements taken at 16 h indicated a return to baseline
values. In the remaining six patients (V to X) the levels of
plasma 5-HT did not change significantly over the 24 h
period of assessment (Figure 1).
Ethical considerations required the use of concomitant
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Figure 1 Plasma levels of 5-hydroxytryptamine (5-HT) in 10
subjects (I to X) measured immediately before the infusion of
cisplatin at time 'O' h and during the 24 h post-infusion period.
antiemetic regimens at the start of cisplatin treatment and
subsequently on patient request. The occurrence or absence
of emesis is presented within this perspective. Patient I, one
bout of emesis at 14 h. Patient II, two bouts of emesis at 8
and 13 h. Patient III, no emesis. Patient IV, no emesis.
Patient V, six bouts of emesis between 9 and 15 h. Patient
VI, three bouts of emesis between 10 and 15 h. Patient VII,
one bout of emesis at 6 h. Patient VIII, two bouts of emesis
at 9 and 14 h. Patient IX, no emesis. Patient X, three bouts
of emesis between 7 and 11 h.
Measurement of plasma levels of 5-HT taken before cis-
platin infusion were comparable to literature values for con-
trol subjects (Ortiz et al., 1988). Values were unchanged
during the 2 h period following cisplatin treatment but the
subsequent marked increase in plasma 5-HT levels in four
patients attained 5-hydroxyindole levels previously found in
the carcinoid syndrome (Feldman et al., 1974; Tyce &
Creagan, 1981). There were temporal differences in the
appearance of the peaks of 5-HT in the plasma; in two
patients the response attained maximum within 4 h while
peaks occurred at 8 h in the other two patients. In the
remaining six patients, at least at the selected times of
measurement, there was no change in plasma 5-HT levels.
However, since the peaks of 5-HT when occurring could
return to baseline values within 2 h, it is possible that the
measurements spaced at 8, 16 and 24h may have failed to
detect changes during these time periods. The study indicates
that a 2 h sampling would be preferred in subsequent studies
to obtain a more detailed profile of biochemical change.
The design of the study to allow patients an appropriate
anti-emetic regimen of lorazepam, metoclopramide and dexa-
methasone precluded a meaningful assessment of changes in
plasma 5-HT to the presence or absence of emesis. That
seven of the ten patients developed varying degrees of emesis
indicates the incomplete nature of emesis control. That two
patients who had markedly increased plasma 5-HT levels
failed to develop emesis may simply reflect a success of the
anti-emetic regimen.
In addition to the attempts to control emesis, patients were
hydrated to reduce the possibility of toxicity. Therefore it is
possible that the hydration/anti-emetic therapy may actually
have contributed to the increased plasma 5-HT levels. But
there is no evidence that lorazepam, metoclopramide or dexa-
methasone or hydration techniques can elevate plasma 5-HT
levels and in any event, in the present study, six patients
treated with such regimens failed to show any change in
plasma 5-HT levels.
In those patients with an elevated circulating 5-HT level
the 5-HT may influence central and or peripheral 5-HT3
receptors to induce emesis (Andrews et al., 1988). Such
patients may be those in whom the 5-HT3 receptor antagon-
ists such as granisetron and ondansetron cause a complete or
major inhibition of emesis (Carmichael et al., 1989; Marty et
al., 1990). However, in the latter studies the 5-HT3 receptor
antagonists were highly effective in at least 75% of patients,
which does not correlate with the 40% of patients only in the
present study showing a raised plasma 5-HT level. Further-
more, Cubeddu et al. (1990) have reported that all patients
treated with cisplatin (at a dose at least twice that of the
present study) had a significant increase in urinary excretion
of 5-hydroxyindoleacetic acid (5-HIAA) which paralleled the
onset and development of emesis. The increases in 5-HIAA
were suggested to reflect the release of 5-HT from entero-
chromaffin cells. Our findings are supportive of the hypo-
thesis that an increase in urinary 5-HIAA levels may reflect
increased levels of plasma 5-HT. In the present study the
lesser incidence of patients showing changes in 5-HT levels
may reflect the small patient sample and lesser dosage
regimen of cisplatin.
A corollary of the above discussion is that the 5-HT3
receptor antagonists would be expected to have little action
in the absence of a raised 5-HT function. In these cases, a
component of emesis could be envisaged to be induced via
other unspecified neurotransmitter system(s) and account for
the small proportion of patients that do not respond to the
5-HT3 receptor antagonists with complete control. The
results of the present study and that of Cubeddu et al. (1990)
indicate the importance of developing these investigations
further using both plasma and urine measurements of 5-HT
and or 5-HIAA, to more fully establish the role of 5-HT in
chemotherapy induced emesis.
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